Sign up
Pharma Capital

VentriPoint Diagnostics exhibiting at globe's largest cardiovascular imaging conference

Last year, the get-together attracted over 3,200 attendees from 90 countries
1512588832_Heart-cells.jpg
VentriPoint has developed a suite of applications for all major heart diseases and imaging modalities

Medtech firm VentriPoint Diagnostics Ltd (CVE:VPT) said it was exhibiting at the EuroEcho- Imaging 2017 conference in Portugal - the world’s largest cardiovascular imaging congress, sending shares higher.

Last year, it attracted over 3,200 attendees from 90 countries last year and is the place to meet.

VentriPoint has developed a suite of applications for all major heart diseases and imaging modalities, including congenital heart disease, left or right heart failure and normal hearts.

“The sales and marketing team is excited about introducing the new 4-chamber VMS heart analysis system to the leading cardiologists for the first time,” said Dr George Adams, the chief executive at Ventripoint. 

“This conference has always been an excellent way to engage customers and learn about their plans for expansion and upgrading their echocardiography services.”

 The conference in Lisbon runs from December 6 to 8.

Shares are up 10% at C$0.28 in Toronto.

Giles_55af4ddca6481.jpg
Why Invest In VentriPoint Diagnostics? Read More Here

Register here to be notified of future VPT Company articles
View full VPT profile

VentriPoint Diagnostics Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.